Shares of Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN), a biopharmaceutical company perhaps most known for its Soliris therapy fell more than 3 percent during Monday’s trading session.
Latest Ratings for ALXN
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Mar 2017 | UBS | Initiates Coverage On | Buy | |
| Mar 2017 | Nomura | Initiates Coverage On | Buy | |
| Dec 2016 | Oppenheimer | Initiates Coverage On | Perform |
View More Analyst Ratings for ALXN
View the Latest Analyst Ratings
May 09, 2017 at 06:21PM
from Jayson Derrick
No comments:
Post a Comment